CME PROGRAM: Novel Applications for Bevacizumab and Other AI Agents
Introduction Bevacizumab is a novel treatment for recurrent glioblastoma (GBM) and has demonst...
MORE  |
|
CME PROGRAM: Combination Therapy
Combination Radiation and Chemotherapy: Targeting Therapy for Newly Diagnosed Glioblastoma Combinati...
MORE |
|
CME PROGRAM: Impact of Extent of Resection of Survival in Glioblastoma
INTRODUCTION Bennett and Godlee's historic report in 1888 describing the initial surgical rese...
MORE |
|
CME PROGRAM: Evolving Respones Criteria
Introduction Levin1 first proposed malignant glioma response criteria in 1977 that utilized brain im...
MORE |
|
CME PROGRAM: Brain Metastases in Cancer
Prevalance of Brain MetastasesIntraparenchymal brain metastases (BM) are the most common neurologica...
MORE |
|
CME PROGRAM: Antiangiogenic Therapies for Malignant Gliomas
What are the indications for antiangiogenic therapies in patients with malignant glioma? Brain...
MORE |
|
CME PROGRAM: Evaluating & Treating Newly Diagnosed Malignant Gliomas
PART I: EVALUATION & INITIAL PRESENTATION Patients who present with a possible malignant glioma ...
MORE |
|
CME PROGRAM: Molecular Markers in GBM
There has been much excitement in neuro-oncology about molecular markers such as methylguanine methy...
MORE |
|
CME PROGRAM: Treating Elderly Patients With the New Standard of Care
Age is a major prognostic factor in patients with malignant gliomas1. Patients older than 50 h...
MORE |
|
CME PROGRAM: MGMT Methylation and Its Role in GBM
Combining temozolomide (TMZ, Temodar®), an oral cytotoxic agent with concomitant radiation thera...
MORE |
|
CME PROGRAM: Long-Term Survival in GBM: Is It Possible?
For patients with newly diagnosed glioblastoma (GBM), conversations about prognosis are becoming inc...
MORE |
|
CME PROGRAM: Evaluating the Role of Functional Imaging
It has become well accepted that optimal treatment of both low- and high-grade gliomas should ...
MORE |
|
